Contact Us
Drug Search Results
More Filters [+]

Foretinib

Alternative Names: foretinib, xl880, gsk1363089
Latest Update: 2024-04-15
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: RTK Inhibitor,C-Met Inhibitor,VEGFR Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Foretinib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Head and Neck Cancer|Gastrointestinal Cancer|Squamous Cell Carcinoma|Non-Small-Cell Lung Cancer|Lung Cancer|Breast Cancer|Renal Cell Carcinoma

Phase 1: Oncology Solid Tumor Unspecified|Hepatocellular Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
IND197

P2

Completed

Breast Cancer

2014-12-14

I198

P2

Completed

Breast Cancer

2014-05-14

NCT02034097

P2

Withdrawn

Non-Small-Cell Lung Cancer

2014-04-01

I196

P2

Completed

Lung Cancer

2014-03-21

Recent News Events

Date

Type

Title

04/15/2024

PubMed

 The HGF/Met Receptor Mediates Cytotoxic Effect of Bacterial Cyclodipeptides in Human Cervical Cancer Cells.

03/11/2024

PubMed

 Design, synthesis, and biological evaluation of new biaryl derivatives of cycloalkyl diacetamide bearing chalcone moiety as type II c-MET kinase inhibitors.

03/01/2024

PubMed

 Foretinib, a c-MET receptor tyrosine kinase inhibitor, tackles multidrug resistance in cancer cells by inhibiting ABCB1 and ABCG2 transporters.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions